日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Linvoseltamab versus real-world International Myeloma Working Group standard-of-care in triple-class exposed relapsed/refractory multiple myeloma

Linvoseltamab 与真实世界中国际骨髓瘤工作组标准治疗方案在三线抗肿瘤治疗后复发/难治性多发性骨髓瘤中的比较

Kumar, Shaji; Jagannath, Sundar; Weisel, Katja C; Rosiñol, Laura; Leleu, Xavier; Dimopoulos, Meletios-Athanasios; Kastritis, Efstathios; Siegel, David S; Monge, Jorge; Du, Juan; de la Rubia, Javier; Asensi Cantó, Pedro; Lee, Jae Hoon; Mateos, María-Victoria; Puertas, Borja; Gozzetti, Alessandro; Dytfeld, Dominik; Ocio, Enrique M; Blade, Joan; Ozaki, Shuji; Beksac, Meral; Escalante, Fernando; Nagaraj, Madhu; Hassan, Rafla; Bonar, Nicolle; Spin, Paul; Shokoohi, Mostafa; Siddiqui, Muhaimen; Wang, Di; Hou, Kevin; West, Michael E D; Hampp, Christian; Green, Jeannette; Humblet, Olivier; Breskin, Alexander; Harnett, James; Ge, Wenzhen; Sobel, Rachel E; Jalbert, Jessica J; Kroog, Glenn S; Rodriguez Lorenc, Karen; Ma, Qiufei; Durie, Brian G M

Patient preferences for triple-class-exposed relapsed or refractory multiple myeloma treatment: a discrete-choice study

患者对接受三类药物治疗的复发或难治性多发性骨髓瘤的偏好:一项离散选择研究

Ailawadhi, Sikander; Inocencio, Timothy J; Mansfield, Carol; Chintakayala, Phani; Bussberg, Cooper; Chi, Lei; Harnett, James; Kroog, Glenn S; Rodriguez-Lorenc, Karen; Ma, Qiufei

A plain language summary of patient preferences for treatments for multiple myeloma that has relapsed or is refractory to prior therapy

一份用通俗易懂的语言总结了复发性或对既往治疗无效的多发性骨髓瘤患者对治疗方案的偏好。

Ailawadhi, Sikander; J Inocencio, Timothy; Mansfield, Carol; Chintakayala, Phani; Bussberg, Cooper; Chi, Lei; Harnett, James; S Kroog, Glenn; Rodriguez-Lorenc, Karen; Ahlstrom, Jenny; Ma, Qiufei

Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma

Linvoseltamab 用于治疗复发/难治性多发性骨髓瘤

Bumma, Naresh; Richter, Joshua; Jagannath, Sundar; Lee, Hans C; Hoffman, James E; Suvannasankha, Attaya; Zonder, Jeffrey A; Shah, Mansi R; Lentzsch, Suzanne; Baz, Rachid; Maly, Joseph J; Namburi, Swathi; Pianko, Matthew J; Ye, Jing Christine; Wu, Ka Lung; Silbermann, Rebecca; Min, Chang-Ki; Vekemans, Marie-Christiane; Munder, Markus; Byun, Ja Min; Martínez-Lopez, Joaquín; Cassady, Kaniel; DeVeaux, Michelle; Chokshi, Dhruti; Boyapati, Anita; Hazra, Anasuya; Yancopoulos, George D; Sirulnik, L Andres; Rodriguez Lorenc, Karen; Kroog, Glenn S; Houvras, Yariv; Dhodapkar, Madhav V

From Triple- to Penta-Exposed Multiple Myeloma: A Real-World Study in a Medicare Population

从三联疗法到五联疗法暴露的多发性骨髓瘤:一项针对医疗保险人群的真实世界研究

Delea, Thomas E; Ma, Qiufei; Kroog, Glenn S; Ge, Wenzhen; Moynahan, Aaron; Sabater Anaya, Natalia; Rodriguez Lorenc, Karen; Song, Xue

Genomic Profiling of Premenopausal HR+ and HER2- Metastatic Breast Cancer by Circulating Tumor DNA and Association of Genetic Alterations With Therapeutic Response to Endocrine Therapy and Ribociclib

通过循环肿瘤DNA对绝经前HR+和HER2-转移性乳腺癌进行基因组分析,并探讨基因改变与内分泌治疗和瑞博西尼治疗反应的关联

Bardia, Aditya; Su, Fei; Solovieff, Nadia; Im, Seock-Ah; Sohn, Joohyuk; Lee, Keun Seok; Campos-Gomez, Saul; Jung, Kyung Hae; Colleoni, Marco; Vázquez, Rafael Villanueva; Franke, Fabio; Hurvitz, Sara; Harbeck, Nadia; Chow, Louis; Taran, Tetiana; Rodriguez Lorenc, Karen; Babbar, Naveen; Tripathy, Debu; Lu, Yen-Shen

Health-related quality of life in premenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer treated with ribociclib plus endocrine therapy: results from a phase III randomized clinical trial (MONALEESA-7)

接受 ribociclib 联合内分泌治疗的激素受体阳性、HER2 阴性晚期乳腺癌绝经前女性的健康相关生活质量:一项 III 期随机临床试验 (MONALEESA-7) 的结果

Harbeck, Nadia; Franke, Fabio; Villanueva-Vazquez, Rafael; Lu, Yen-Shen; Tripathy, Debu; Chow, Louis; Babu, Govind K; Im, Young-Hyuck; Chandiwana, David; Gaur, Anil; Lanoue, Brad; Rodriguez-Lorenc, Karen; Bardia, Aditya